Used in targeted cancer therapy, particularly for solid tumors expressing LRRC15, such as certain breast, lung, and pancreatic cancers. Acts as a blocking agent that interferes with tumor microenvironment signaling, potentially inhibiting cancer cell growth and metastasis. Also utilized in diagnostic imaging to detect LRRC15-positive tumors and monitor treatment response. Investigated in antibody-drug conjugates (ADCs) to deliver cytotoxic agents directly to cancer cells, improving therapeutic precision and reducing off-target effects. Currently in clinical development for immuno-oncology applications.